# CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:** 

206073Orig1s000

**CHEMISTRY REVIEW(S)** 



### FDA CDER EES **ESTABLISHMENT EVALUATION REQUEST** SUMMARY REPORT

Application:

NDA 206073/000

Sponsor:

**BOEHRINGER INGELHEIM** 

^ode:

510

900 RIDGEBURY RD RIDGEFIELD, CT 06877

Stamp Date:

30-JAN-2014

**Brand Name:** 

**EMPAGLIFLOZIN AND LINAGLIPTIN TABLETS** 

PDUFA Date:

30-JAN-2015

Estab. Name:

**EMPAGLIFLOZIN AND LINAGLIPTIN TABLETS** 

**Action Goal:** 

Generic Name:

**District Goal:** 

30-AUG-2014

Product Number: Dosage Form; Ingredient; Strengths

001 T식당'LET; LINAGLIPTIN; 5MG 001; TABLET; EMPAGLIFLOZIN; 10MG 002; TABLET; LINAGLIPTIN; 5MG

002; TABLET; EMPAGLIFLOZIN; 25MG

FDA Contacts: J. LEGINUS

Prod Qual Reviewer

(HFD-810)

LINAGLIPTIN

3017964102

E. PFEILER

Micro Reviewer

(HF-22)

3017960642

P. KUMAR

Product Quality PM

(HFD-800)

2404023722

C. CAPPEL-LYNCH

Regulatory Project Mgr

3017988436

Overall Recommendation:

**ACCEPTABLE** 

on 22-JUL-2014

by R. SAFAAI-JAZI

()

3017964463

**Establishment:** 

9610492

CFN:

FEI:

3002306556

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

BINGER STREET 173

INGELHEIM AM RHEIN, RHEINLAND-PFALZ, GERMANY

DMF No:

FINISHED DOSAGE MANUFACTURER

a:

onsibilities:

TABLETS, PROMPT RELEASE

OAL Status:

AADA:

NONE

**Last Milestone:** 

OC RECOMMENDATION

Milestone Date:

10-JUN-2014

Decision:

**ACCEPTABLE** 

Reason:

DISTRICT RECOMMENDATION

Establishment:

CFN:

1510690

FEI: 1510690

BOEHRINGER INGELHEIM ROXANE INC

DMF No:

COLUMBUS, , UNITED STATES 432289579

Responsibilities:

FINISHED DOSAGE LABELER

FINISHED DOSAGE PACKAGER

Profile:

TABLETS, PROMPT RELEASE

OAI Status:

A. Same

NONE

Last Milestone:

OC RECOMMENDATION

**Milestone Date:** 

12-FEB-2014

Decision:

**ACCEPTABLE** 

Reason:

BASED ON PROFILE

January 21, 2015 6:44 AM

FDA Confidential - Internal Distribution Only

Page 1 of 3



# FDA CDER EES ESTABLISHMENT EVALUATION REQUEST SUMMARY REPORT

Establishment:	',	(b) (4)	FEI:	(b) (4)		
DMF No:					AADA:	
Responsibilities:	ANISHED DOSAG	HOTHER TE	STER			
Profile:	CONTROL TESTIN	NG LABORAT	ORY		OAI Status:	NONE
Last Milestone:	OC RECOMMEND	DATION				
Milestone Date:	25-FEB-2014					
Decision:	ACCEPTABLE					
Reason:	DISTRICT RECOM	MENDATION				
Establishment:	OFN:	· · · · · · · · · · · · · · · · · · ·	FEI:	(b) (4)		
Establishment,	377.44	(	(b) (4)			
DMF No:					AADA:	
Responsibilities:	SMISHED DOSAG	E OTHER TE	STER			
Profile:	CONTROL TESTIN	IG LABORAT	ORY		OAI Status:	NONE
Last Milestone:	OC RECOMMEND	ATION				
Milestone Date:	25-FEB-2014					
Decision:	ACCEPTABLE					
Reason:	DISTRICT RECOM	MENDATION				
Establishment:	CFN:	and a copyright, we have ready as the second	FEI:	(b	) (4)	
			(b) (4)			
DMF No:					AADA:	
Responsibilities:	FINISHED DOSAG	E OTHER TE	STER			
Profile:	CONTROL TESTIN	NG LABORAT	ORY		OAI Status:	NONE
Last Milestone:	OC RECOMMEND	ATION				
Milestone Date:	12-FEB-2014					
Decision:	ACCEPTABLE					
Reason:	BASED ON PROF	ILE				



January 21, 2015 6:44 AM

# FDA CDER 1255 ESTABLISHMENT EVALUATION REQUEST SUMMARY REPORT

Establishment:	CFN: F	(b) (4)						
DMF No:			AADA:					
Responsibilities:	FINISHED DOSAGE LABELER		The total control of the control of					
noopono.amaoa	FINISHED DOSAGE PACKAGER							
Profile:	TABLETS, PROMPT RELEASE CATEBURS. NONE							
Last Milestone:	OC RECOMMENDATION							
Milestone Date:	22-JUL-2014							
Decision:	ACCEPTABLE							
Reason:	DISTRICT RECOMMENDATION							
Establishment:	(b) (4)	(b) (4)*~		Market 12 Market Market Market 1 Market 1 Market Market 1				
		(U) (4)						
DMF No:			AAD::					
			AGEN:					
DMF No: Responsibilities:	FINISHED DOSAGE LABELER FINISHED DOSAGE PACKAGER		AAba					
	FINISHED DOSAGE LABELER		AADA: OAl Status:	NONE				
Responsibilities:	FINISHED DOSAGE LABELER FINISHED DOSAGE PACKAGER			NONE				
Responsibilities: Profile:	FINISHED DOSAGE LABELER FINISHED DOSAGE PACKAGER TABLETS, PROMPT RELEASE			NONE				
Responsibilities:  Profile:  Milestone:	FINISHED DOSAGE LABELER FINISHED DOSAGE PACKAGER TABLETS, PROMPT RELEASE OC RECOMMENDATION			NONE				

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.
/s/
MARY GRACE LUBAO 02/09/2015



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

